目前针对 MASH 的治疗手段极为有限，仅有一种药物获批。法尼醇 X 受体（FXR，NR1H4）作为治疗 MASH 的热门靶点，其激动剂奥贝胆酸（OCA）虽已进入 III 期临床试验，但广泛激活 FXR 会破坏胆固醇稳态，引发副作用。部分激动剂虽被寄予厚望，可具体效果和潜在机制 ...

Ongoing research is also exploring FASN inhibitors to reduce lipids, NR1H4/FXR agonists to address bile acid-related injuries, GLP-1R agonists to improve insulin sensitivity, and FGF19/FGF21 ...